Latest Research, Industry, Medical and Scientific News
Axena Health Begins First-of-Its-Kind Global Study of Female Incontinence
Axena Health, Inc. (Axena Health), a women’s health medical device company focused on scalable treatments for female pelvic health, announced today a large-scale study that will investigate the burdens of incontinence on women in low- and middle-income countries to support equitable access to treatment. The first-of-its-kind study will examine how women could access treatment within local healthcare delivery systems and in a manner that accommodates cultural norms. Study results will be available in late 2023 and will inform the development of new treatment options based on the Leva® Pelvic Health System, a digital health treatment for urinary incontinence (UI) with published studies supporting its effectiveness, including durable, long-term symptom relief. Read more.
Source: Yahoo! Finance, May 19, 2023
Megola Completes Successful Pilot Scale-Up Field Testing of its Patent-Pending Odor Control (SAPs) for Baby Diapers, Adult Incontinence and Feminine Hygiene Products
Megola, Inc. (“MGON”, “Company”) a Consortium Group of Health Technologies and Eco-Friendly Product Lines announced the successful completion of its Pilot Scale-up Field Testing with its patent-pending Odor Control (SAPs) for Baby Diapers, Adult Incontinence and Feminine Hygiene Products. The odor control personal hygiene products were provided to a group of incontinent human volunteers in the USA. Superabsorbent Polymer granules (SAP) are used annually in diapers and pads of all types, in a global industry with an annual turnover of more than $100 billion. “It’s been a long time coming but controlling embarrassing odors from incontinence garments and feminine hygiene products is about to become a reality at last….” Read more.
Source: StreetInsider.com, May 8, 2023
Acupuncture for Women With Overactive Bladder
The most common symptom of an overactive bladder is a sudden, uncontrolled need or urge to urinate; followed by the need to urinate excessively throughout the day and night, independent of fluid intake. In women, causes of overactive bladder are varied, but the common consequence, beyond the physical manifestations, are frustration and embarrassment. While medications designed to relax the bladder remain a frontline treatment option, research continues to show the potential of nonpharmaceutical options – including acupuncture. Case in point: a 2023 research review that concludes acupuncture is effective and safe for treating overactive bladder. Read more.
Source: Acupunture Today, May/June 2023
World’s First Bladder Transplant Will Be Performed By Both Human and Robot Surgeons
A team of urologists at Keck Medicine of the University of South California (USC) is conducting a clinical trial that will soon lead to the first-ever bladder transplant operation in humans. The doctors are currently in the process of selecting participants for their trials. If successful, such operations would provide relief to millions of people around the globe who live with bladder-related disorders. Inderbir Gill, principal investigator and executive director at Keck Medicine USC Urology, said, “We could be on the verge of a medical advance that has the potential to revolutionize how we treat terminally compromised bladders.” Read more.
Source: Interesting Engineering, May 2, 2023
Women’s Health Leader Elidah Launches Game-changing ELITONE URGE Device To Treat Overactive Bladder
Providing the same relief for overactive bladder (OAB) that they’ve become known for in the stress urinary incontinence arena, MedTech Elidah is excited to introduce their newest product, ELITONE URGE (https://elitone.com/products/), the first and only non-intrusive treatment for urge incontinence. This latest device, a natural successor to ELITONE, is specified to treat urgency bladder leaks that afflict 33 million women in the United States alone. ELITONE URGE is an external, non-implanted muscle stimulator that outputs signals to calm the muscles and nerves that cause urgency or OAB leaks. The patented design maximizes comfort and efficacy, while being discreet and wearable under clothes, for the perfect urge incontinence therapy.
Source: Globe Newswire, May 2, 2023
Clinical Study Results of the BlueWind System for Patients with Overactive Bladder Featured at the 2023 AUA Annual Meeting
BlueWind Medical, Ltd., the developer of a transformative implantable tibial neuromodulation therapy for Overactive Bladder (OAB), today announced results from the OASIS pivotal trial evaluating the safety and efficacy of the BlueWind System in the treatment of OAB. The results were featured in the late-breaking session (LBA01-05) at the American Urological Association (AUA) 2023 Annual Meeting in Chicago on Sunday, April 30th. Read more.
Source: PRNewswire, May 1, 2023